Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 18, 2026

Palantir Stock Has Made Its Early Investors Rich. Can It Do It Again?

View original at nasdaq.com
Palantir Stock Has Made Its Early Investors Rich. Can It Do It Again? Key Points Since Palantir Technologies went public a little over five years ago, its shares have gained an enormous amount of value…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Palantir's top line is expected to top $10 billion in 2027

    60% confidence
  • The Motley Fool Stock Advisor team identified 10 best stocks for investors to buy now, and Palantir Technologies was not one of them

    60% confidence
  • Stock Advisor's total average return is 1,016% compared to 197% for the S&P 500

    60% confidence
  • Palantir is expected to report $2.56 per share earnings in 2028

    60% confidence
  • Alphabet and Microsoft are well-positioned to penetrate the decision intelligence market through quantum computing integration

    60% confidence
  • There is no real barrier to entry into the decision intelligence market, particularly for companies like Microsoft or Alphabet that already have many of the technical resources needed

    60% confidence
  • Palantir's per-share profits of $0.63 in 2024 are projected to triple by 2027, and grow another 40% in 2028

    60% confidence
  • The decision intelligence software market will grow by more than 15% per year through 2035

    60% confidence
  • Competition will reduce pricing power and put pressure on profit margins that Palantir hasn't faced yet

    60% confidence
  • Palantir stock probably cannot repeat its 1,700% performance over the next five years

    60% confidence

Data points we hold from this source

S&P 500 · price to earnings ratio25 ratio
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com